After One-Off Cash Infusions, YZY Biopharma Looks for More Funds From IPO
The cash-challenged biotech firm specializing in BsAbs and immuno-oncology therapies is turning to a Hong Kong listing to try to replenish its coffersKey Takeaways:YZY Biopharma has filed for a Hong…
RELATED ARTICLES
-
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK -
Novel drugs lift Sino Biopharm earnings, easing price-cap pain
1177.HK
- Increasing losses prompt Zephyrm Bioscience to seek funds through IPO
-
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
1672.HK
- Jiuyuan Gene seeks IPO cash for bet on weight-loss drugs
-
Akeso marks profit milestone with swift rights issue
9926.HK
